The Role of Tofacitinib in the Treatment of Acute Severe Colitis in Children
Journal of the Canadian Association of Gastroenterology · 08.04.2024 · 7 (2) · 196-203
DOI: 10.1093/jcag/gwad042 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the Canadian Association of Gastroenterology, online erschienen am 06.11.2023. Verfasst von Guillermo Alejandro Costaguta und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology, Department of Pediatrics, CHU Sainte-Justine, 3175 Chem de la Côte-Sainte-Catherine, H3T 1C5, Montreal, Quebec, Canada. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Objectives
Acute severe colitis (ASC) occurs in up to 15 percent of children with ulcerative colitis, with a high index of morbidity and mortality. Treatment includes high-dose steroids, infliximab, and salvage therapies. Unfortunately, up to 20 percent of patients may need an urgent colectomy due to treatment failure. We report our experience using tofacitinib for the treatment of six patients.
Methods
A retrospective review of our medical electronic records was conducted. We included every patient with ASC and treatment failure, in whom tofacitinib was used as a salvage therapy. Response, complications, and disease course were noted.
Results
Six patients were included with Pediatric Ulcerative Colitis Activity Index (PUCAI) scores ranging from 65 to 85 on admission, and 35 to 85 before tofacitinib was started (P 0.07). Median response time was 72 h. A median decrease of 40 points in PUCAI was noted (P 0.00001). Mean length of stay was 18 days with discharge 9 days after tofacitinib introduction. Haemoglobin, albumin, fecal calprotectin, and CRP improved after tofacitinib (P 0.02, P 0.02, P 0.025, and P 0.01, respectively). The mean follow-up was 8.5 months, four patients achieved complete remission and only one had a recrudescence of symptoms (P 0.01). One patient had a systemic Epstein-Barr virus infection prior to tofacitinib therapy, which resolved with rituximab treatment. No other complications were noted.
Conclusions
Tofacitinib response is rapid and impressive in children suffering from ASC, and the safety profile appears comparable to or better than other available treatments. In the future, tofacitinib should be integrated into pediatric protocols.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Gastroenterology, Department of Pediatrics, CHU Sainte-Justine, 3175 Chem de la Côte-Sainte-Catherine, H3T 1C5, Montreal, Quebec, Canada.
- Department of Pediatrics of the Faculty of Medicine, Université de Montreal, Montreal, Quebec, Canada.
ORCID-Profile: Guillermo Alejandro Costaguta
Zitieren
APA
Costaguta, G. A., Girard, C., Groleau, V., Grzywacz, K., Dirks, M. H., & Deslandres, C. (2024). The Role of Tofacitinib in the Treatment of Acute Severe Colitis in Children. Journal of the Canadian Association of Gastroenterology, 7(2), 196-203. https://doi.org/10.1093/jcag/gwad042
Vancouver
Costaguta GA, Girard C, Groleau V, Grzywacz K, Dirks MH, Deslandres C. The Role of Tofacitinib in the Treatment of Acute Severe Colitis in Children. Journal of the Canadian Association of Gastroenterology. 2024;7(2):196-203. doi:10.1093/jcag/gwad042
BibTeX
@article{Costaguta2024,
author = {Costaguta, Guillermo Alejandro and Girard, Chloé and Groleau, Véronique and Grzywacz, Kelly and Dirks, Martha Heather and Deslandres, Colette},
title = {The Role of Tofacitinib in the Treatment of Acute Severe Colitis in Children},
journal = {Journal of the Canadian Association of Gastroenterology},
year = {2024},
volume = {7},
number = {2},
pages = {196--203},
doi = {10.1093/jcag/gwad042}
}
EUVIMED